Skip to textbook content
Doctor’s PassportTextbook
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…

Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.

Erythema multiforme

Dermatology · UK scope · Sources checked 27 Aug 2026 · Clinical review pending

RapidFull
!
Suspected SJS or severe mucosal compromise

Skin pain, rapidly spreading dusky macules or flat atypical targets, blistering or detachment, fever and severe involvement of two or more mucosal sites after a medicine are not routine erythema multiforme; dehydration, ocular injury and airway or genital scarring can evolve quickly.

Action: Stop any suspect non-essential medicine, assess airway, eyes, mouth, genital and urinary function and arrange emergency hospital and dermatology review with supportive resuscitation; obtain ophthalmology and other site-specific specialist input early rather than waiting for extensive detachment.

Synopsis

Recognise true target lesions and mucosal severity across skin tones, identify infection-related triggers, separate erythema multiforme from Stevens–Johnson syndrome, and treat acute and recurrent disease safely.

  • A classic erythema-multiforme target is a fixed round lesion with three concentric zones: a dusky or blistered centre, a paler oedematous ring and a sharply defined outer erythematous rim.
  • Lesions arise symmetrically on backs of hands, feet and extensor limbs and spread centripetally; they remain in the same place for days, unlike individual urticarial wheals.
  • On brown or black skin, the outer ring may be purple-brown and central duskiness grey or deep brown; palpability, oedema, blistering and the concentric outline may be clearer than red colour.
  • Herpes simplex virus is the common recurrent trigger and the target eruption often begins about ten days after a cold sore, although the herpes lesion may already have resolved.
  • Erythema multiforme major includes significant mucosal disease but remains clinically distinct from Stevens–Johnson syndrome and toxic epidermal necrolysis.
  • Prominent respiratory-associated mucositis with few skin lesions suggests reactive infectious mucocutaneous eruption rather than forcing every case into erythema multiforme.
  • Diagnosis is usually clinical; biopsy is useful for atypical, persistent or high-stakes presentations but histology must be interpreted with distribution, medicines, mucosa and skin pain.
  • First-line limited disease care is trigger review, emollient and symptom relief; severe mouth disease needs analgesia, hydration and assessment of nutrition, eyes and other mucosae.
  • Frequent HSV-associated recurrences merit continuous antiviral suppression, commonly aciclovir 400 mg twice daily for at least six months with specialist review.

Key red flags

Skin pain, systemic toxicity, rapidly expanding central duskiness, epidermal detachment, inability to drink, reduced urine, breathing difficulty, visual symptoms, genital erosions, pregnancy, immunosuppression or diagnostic uncertainty requires same-day specialist assessment.

Mucosal erythema multiforme

Painful oral erosions and haemorrhagic lip crust can accompany classic skin targets; ocular, genital or airway symptoms increase severity and referral need.

SJS or TEN pattern

Fever, skin pain, flat atypical truncal targets, purpura, extensive mucositis and detachment after medication indicate a different emergency phenotype.

Investigation priorities

01
Whole-skin and mucosal examinationFirst step

Confirm target morphology, map severity and identify an SJS or TEN pattern.

Management branches

First diagnostic sequenceVerify targets before naming the eruption

A sudden symmetrical annular or targetoid eruption is reported.

  1. Establish whether individual lesions are fixed for days and have three palpable zones, then map acral versus truncal distribution and photograph representative sites with consent.
  2. Examine all mucosae, measure skin pain and detachment and record systemic observations before asking about HSV, respiratory infection and a complete medicine timeline.
  3. Manage as possible SJS or TEN and seek same-day dermatology advice if targets are flat or atypical, pain or toxicity is prominent, multiple mucosae are severe or the diagnosis remains uncertain.
First-line limited careRelieve symptoms and remove the active trigger

Classic targets are limited, the patient is systemically well and oral intake is secure.

  1. Explain the usual self-limited two-to-four-week course, use cool emollients and a short site-appropriate topical corticosteroid course for inflamed itchy plaques.
  2. Use a non-sedating oral antihistamine when itch is troublesome and simple analgesia when safe, while avoiding unneeded new medicines during diagnostic evolution.

Key medicines

Site-appropriate topical corticosteroidApply a thin layer once daily to inflamed intact target plaques for up to seven to fourteen days, selecting potency by site and reviewing if blistering or spread continues.Avoid potent products on eyelids, face or folds without supervision and do not apply into infected or deeply eroded skin; local improvement must not delay reassessment for SJS or mucosal compromise.
Aciclovir recurrent-disease suppressionTake 400 mg by mouth twice daily continuously for at least six months when recurrent HSV-associated erythema multiforme is confirmed, then review the need for continuation.Adjust for renal impairment, maintain hydration and review neurotoxicity, nephrotoxicity, pregnancy and interacting nephrotoxic medicines; breakthrough lesions should trigger adherence and diagnostic review, not automatic dose escalation.
Open full textbook →Answer 2 questions
Sources and review status4 sources · checked 27 Aug 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

  • British Association of Dermatologists erythema multiformeTarget morphology, HSV association, distinction from SJS and recurrent-disease treatment.
  • NHS erythema multiformeAccessible recognition, urgent features, triggers and treatment advice.
  • Primary Care Dermatology Society erythema multiformeClinical patterns, differential diagnosis and referral thresholds.
  • Aciclovir 200 mg UK SmPCSuppression regimen, renal adjustment, interactions and adverse effects.

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes

Authoring stateRapid draftClinical stateAwaiting reviewJurisdictionUnited Kingdom
Treat active herpes according to its own indication and give return precautions for new mucosal pain, inability to drink, eye or genital symptoms, skin pain, blistering or spreading duskiness.